Pre-made Vandortuzumab benchmark antibody ( Whole mAb ADC, anti-STEAP1 therapeutic antibody, Anti-PRSS24/STEAP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vandortuzumab biosimilar, Whole mAb ADC, Anti-STEAP1 Antibody: Anti-PRSS24/STEAP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer. This drug was developed by Genentech/Roche. Development was discontinued in 2017.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-610-1mg	1mg	4635
GMP-Bios-ab-610-10mg	10mg	Inquiry
GMP-Bios-ab-610-100mg	100mg	Inquiry
GMP-Bios-ab-610-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Vandortuzumab biosimilar, Whole mAb ADC, Anti-STEAP1 Antibody: Anti-PRSS24/STEAP therapeutic antibody
INN Name	Vandortuzumab
Target	STEAP1
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Roche;Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Cancers;Prostate Cancer
Development Tech	na